Staidson (Beijing) BioPharmaceuticals Co., Ltd. (SHE:300204)

SHE:300204 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	173.17	53.91	85.18	264.99	85.01	140.57
Short-Term Investments	-	-	-	-	-	120.73
Trading Asset Securities	-	-	-	-	381.46	461.24
Cash & Short-Term Investments	173.17	53.91	85.18	264.99	466.47	722.54
Cash Growth	298.17%	-36.71%	-67.86%	-43.19%	-35.44%	-8.52%
Accounts Receivable	38.72	39.07	61.22	188.18	157.9	128.22
Other Receivables	0.91	0.64	1.14	1.38	1.18	1.29
Receivables	39.63	39.72	62.35	189.56	159.07	129.51
Inventory	20.93	22.18	20.93	18.83	25.01	38.09
Prepaid Expenses	-	0.01	0.01	-	-	-
Other Current Assets	65.94	61.8	70.41	55.69	37.9	13.17
Total Current Assets	299.66	177.62	238.89	529.06	688.44	903.32
Property, Plant & Equipment	222.87	235	261.36	290.58	312.43	295.17
Long-Term Investments	477.07	514.07	549.54	522.25	545.43	444.03
Goodwill	19.75	19.75	19.75	19.75	22.17	22.17
Other Intangible Assets	36.84	34.67	35.13	80.48	82.22	82.97
Long-Term Deferred Tax Assets	50.08	50.08	164	198.13	155.84	79.87
Long-Term Deferred Charges	134.08	117.84	62.57	26.97	5.29	20.51
Other Long-Term Assets	2.63	0.58	0.98	2.09	15.15	8.17
Total Assets	1,243	1,150	1,332	1,669	1,827	1,856
Accounts Payable	20.65	33.49	72.91	35.87	31.71	19.63
Accrued Expenses	10.6	67.71	83.85	158.73	150.01	127.99
Short-Term Debt	20.01	42.42	40.95	23.09	-	48
Current Portion of Leases	-	0.06	-	2.69	2.25	-
Current Income Taxes Payable	-	-	-	0.02	-	-
Current Unearned Revenue	3.9	3.89	2.86	3.27	1.34	1.14
Other Current Liabilities	60.91	6.88	7.6	8.1	11.33	11.43
Total Current Liabilities	116.08	154.45	208.17	231.77	196.64	208.2
Long-Term Leases	-	0.06	-	3.18	5.37	-
Long-Term Unearned Revenue	28.23	29.91	29.24	33.47	21.32	23.35
Long-Term Deferred Tax Liabilities	48.5	48.43	74.14	47.03	52.91	33.83
Other Long-Term Liabilities	-	-	-	-	-	3.32
Total Liabilities	192.81	232.85	311.55	315.45	276.25	268.7
Common Stock	477.77	477.77	477.77	475.36	476.03	476.03
Additional Paid-In Capital	747.41	570.95	534.46	519.36	536.44	531.08
Retained Earnings	-274	-249.37	-83.63	314.62	510.98	648
Treasury Stock	-	-	-	-	-43.68	-82.72
Comprehensive Income & Other	96.12	129.88	92.06	44.53	70.97	15.11
Total Common Equity	1,047	929.23	1,021	1,354	1,551	1,588
Minority Interest	2.87	-12.47	-	-	-	-
Shareholders' Equity	1,050	916.76	1,021	1,354	1,551	1,588
Total Liabilities & Equity	1,243	1,150	1,332	1,669	1,827	1,856
Total Debt	20.01	42.54	40.95	28.96	7.63	48
Net Cash (Debt)	153.15	11.37	44.23	236.03	458.84	674.54
Net Cash Growth	801.50%	-74.28%	-81.26%	-48.56%	-31.98%	-14.60%
Net Cash Per Share	0.27	0.02	0.09	0.49	0.97	1.42
Filing Date Shares Outstanding	-	477.77	477.77	475.36	472.66	469.65
Total Common Shares Outstanding	-	477.77	477.77	475.36	472.66	469.65
Working Capital	183.58	23.18	30.72	297.28	491.8	695.12
Book Value Per Share	-	1.94	2.14	2.85	3.28	3.38
Tangible Book Value	990.71	874.81	965.78	1,254	1,446	1,482
Tangible Book Value Per Share	-	1.83	2.02	2.64	3.06	3.16
Buildings	-	215.93	214.75	184.57	183.64	183.07
Machinery	-	317.62	318.38	254.98	246.28	237.66
Construction In Progress	-	-	-	87.82	85.48	52.92

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.